Skip to main content

Table 1 Patient demographic details

From: Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis

Age Gender Time since diagnosis (months) Time since commencing adalimumab (months) Ocular complications Active joint count at time of review Uveitis activity at time of review *
6 F 37 24 Nil 0 Right 0
Left 0
8 F 72 13 Nil 0 Right 2+
Left 2+
10 M 66 58 Cataract, posterior synechiae, ocular hypertension 0 Right 0.5+
Left 0.5+
11 F 82 27 Nil 1 Right 0.5+
Left 0.5+
12 M 43 25 Cataract 0 Right 0.5+
Left 0.5+
12 F 127 80 Posterior synechiae 0 Right 0
Left 0
13 M 143 122 Cataract, posterior synechiae, band keratopathy 0 Right 0
Left 0.5+
15 F 172 21 Nil 0 Right 0.5+
Left 0.5+
17 F 190 59 Nil 0 Right 0.5+
Left 0.5+
  1. *anterior chamber cell grading as per standardization of uveitis nomenclature (SUN) criteria [24]